# Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants

> **NCT00139347** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6360 (—)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** 2-dose oral live attenuated G1P[8] human rotavirus vaccine

## Key facts

- **NCT ID:** NCT00139347
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 6360 (—)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00139347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00139347, "Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00139347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*